FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gynecology, can be used for prediction of myomatous assembly expulsion following uterine artery embolization (UAE) in a patient with uterine myoma. That is ensured by immunohistochemical examination of biopsy material of myomatous node in a patient with uterine myoma before UAE. Following genes are measured: VEGF, CD-117, Desmin, Actin, Vimentin, Ki-67. If observing VEGF values of 40 %, CD-117 15 %, Desmin 100 %, Actin 100 %, Vimentin 100 % and Ki-67 10 %, the myomatosis unit is predicted to expel.
EFFECT: method enables selecting the optimal approach to administering the patients with hysteromyoma after the UAE, reducing the risk of bleeding, eliminating intra- and postoperative complications caused by the surgical intervention, while maintaining fertility in the patients of reproductive age.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF RECURRENCE OF SYMPTOMATIC UTERINE MYOMA AFTER SELECTIVE EMBOLIZATION OF UTERINE ARTERIES | 2021 |
|
RU2766809C1 |
| METHOD FOR TRANSRADIAL ENDOVASCULAR EMBOLISATION OF UTERINE ARTERIES | 2014 |
|
RU2551947C1 |
| METHOD FOR PREDICTION OF ENDOMETRIAL HYPERPLASIA IN PATIENTS WITH HYSTEROMYOMA FOLLOWING UTERINE ARTERY EMBOLISATION | 2014 |
|
RU2558052C1 |
| METHOD FOR DETERMINING NON-TARGET UTERINE ARTERY EMBOLIZATION | 2021 |
|
RU2768142C1 |
| METHOD FOR PREDICTION OF HYSTEROMYOMA REGRESSION | 2015 |
|
RU2596093C1 |
| METHOD FOR COMBINED TREATMENT OF UTERINE MYOMAS | 2019 |
|
RU2730926C1 |
| METHOD FOR TREATING HYPERPLASTIC ENDOMETRIAL PROCESSES COMBINED WITH UTERINE MYOMA | 2006 |
|
RU2317103C1 |
| PREVENTION METHOD FOR POSTOPERATIVE COMPLICATIONS INVOLVING EMBOLISED UTERINE ARTERIES IN UTERUS MYOMAS | 2008 |
|
RU2364335C1 |
| METHOD FOR PREDICTION OF CHARACTER OF UTERINE INVOLVEMENT IN MYOMATOUS NODES | 2010 |
|
RU2453850C2 |
| METHOD FOR SURGICAL TREATING UTERINE MYOMA | 2002 |
|
RU2223700C1 |
